Editorial reviews. Affiliate fees from some providers don't affect rankings. Disclosure

No advertiser influenceAffiliate fees disclosedReviewed by board-certified clinicians

Free notification service

Get alerted the moment things change

We watch ~50 telehealth brands daily. When pricing drops, shortage status shifts, or enforcement actions land — you get an email. Segment by topic, no filler. Average ~2 emails/month per topic.

What triggers an alert

  • 10%+ price dropBrand cuts price by 10% or more on any tier — alert within 24h
  • FDA shortage status changeWhen semaglutide/tirzepatide/estradiol moves on/off FDA shortage list
  • New compounded optionA new 503A/503B pharmacy partnership launches with verified brands
  • Enforcement actionFDA warning letter, FTC settlement, or state board action against a covered brand
  • Dosage availability changeNew dose strength FDA-approved or compounded version becomes available

Pick your alerts

Which alerts do you want? (pick at least one)

We send max 1 email per topic per week. Unsubscribe one click. No sharing with brands.

Why we built this

Telehealth pricing changes fast — compounded GLP-1 prices dropped 30% on average 2024-2025. Insurance coverage shifts mid-year. FDA shortage status (which enables/disables compounding) flips quarterly. Without alerts, you make decisions based on stale data. This is editorial public service — no paid placement, not tied to affiliate revenue.